RNS Number : 0490A
N4 Pharma PLC
31 January 2022

31 January 2022

N4 Pharma Plc

("N4 Pharma" or the "Company")

Granting of Patents

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, announces that the University of Queensland has informed the Company that it has been notified by the US patent attorney of the granting of its patent application in relation to Nuvec® in the United States and by the Chinese authorities of the granting of a patent in China. N4 Pharma has the exclusive worldwide rights to Nuvec® for therapeutic uses in humans and animals.

The granted patent in the USA will specifically cover the matter of composition of the nanoparticle made using a broad description of the manufacturing process used by the Company. The University of Queensland has also informed the Company it will file a continuation patent application in the USA for a matter of composition patent independent of the manufacturing process to match the patents granted in Europe, Japan, Australia and China.

Nigel Theobald, Chief Executive Officer of the Company, commented: "We are delighted to receive notification of this allowance to grant our licensed patent in these critical and influential markets.

"The granting of this USA nanoparticle patent using a broad description of the manufacturing process adds to the other granted patents giving us strong intellectual property protection in the key territories across the world which is a vital component for potential licensing deals"

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 which has been incorporated into UK law by the European Union (Withdrawal) Act 2018.

Enquiries:

N4 Pharma Plc **Via IFC Advisory**

Nigel Theobald, CEO

Luke Cairns, Executive Director

SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470

Nominated Adviser and Joint Broker

Matthew Johnson/Caroline Rowe (Corporate Finance)

Vadim Alexandre/Rob Rees (Corporate Broking)

Turner Pope Investments (TPI) Limited **Tel: +44 (0)20 3657 0050**

Joint Broker

Andy Thacker

IFC Advisory Limited **Tel: +44 (0)20 3934 6630**

Financial PR

Graham Herring

Zach Cohen

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as

part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCBKFBNOBKDPDB